Agenus announces botensilimab and balstilimab presentations at asco 2025

Lexington, mass.--(business wire)--agenus inc. (nasdaq: agen), a leader in immuno-oncology, today announced three upcoming presentations at the 2025 american society of clinical oncology (asco) annual meeting, taking place may 30 – june 3 in chicago, illinois. a poster presentation will highlight new translational data monitoring induced t-cell dynamics from the botensilimab and balstilimab (bot/bal) program in mismatch repair–proficient (pmmr)/microsatellite stable (mss) metastatic colorectal.
AGEN Ratings Summary
AGEN Quant Ranking